- Home
- DPG vs DCTH Comparison
DPG vs DCTH Comparison
Compare DPG & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DPG
- DCTH
- Stock Information
- Founded
- DPG 2011
- DCTH 1988
- Country
- DPG United States
- DCTH United States
- Employees
- DPG N/A
- DCTH N/A
- Industry
- DPG Trusts Except Educational Religious and Charitable
- DCTH Medical/Dental Instruments
- Sector
- DPG Finance
- DCTH Health Care
- Exchange
- DPG Nasdaq
- DCTH Nasdaq
- Market Cap
- DPG 465.2M
- DCTH 394.9M
- IPO Year
- DPG N/A
- DCTH N/A
- Fundamental
- Price
- DPG $12.79
- DCTH $11.12
- Analyst Decision
- DPG
- DCTH Strong Buy
- Analyst Count
- DPG 0
- DCTH 4
- Target Price
- DPG N/A
- DCTH $24.50
- AVG Volume (30 Days)
- DPG 150.1K
- DCTH 834.5K
- Earning Date
- DPG 01-01-0001
- DCTH 08-06-2025
- Dividend Yield
- DPG 9.09%
- DCTH N/A
- EPS Growth
- DPG N/A
- DCTH N/A
- EPS
- DPG N/A
- DCTH 0.06
- Revenue
- DPG N/A
- DCTH $70,240,000.00
- Revenue This Year
- DPG N/A
- DCTH $160.46
- Revenue Next Year
- DPG N/A
- DCTH $42.87
- P/E Ratio
- DPG N/A
- DCTH $198.75
- Revenue Growth
- DPG N/A
- DCTH 491.35
- 52 Week Low
- DPG $7.90
- DCTH $7.83
- 52 Week High
- DPG $13.58
- DCTH $18.23
- Technical
- Relative Strength Index (RSI)
- DPG 63.68
- DCTH 50.82
- Support Level
- DPG $12.60
- DCTH $10.06
- Resistance Level
- DPG $12.80
- DCTH $10.81
- Average True Range (ATR)
- DPG 0.11
- DCTH 0.75
- MACD
- DPG 0.00
- DCTH 0.12
- Stochastic Oscillator
- DPG 86.67
- DCTH 35.01
About DPG Duff & Phelps Utility and Infrastructure Fund Inc.
Duff & Phelps Utility & Infrastructure Fund Inc. is an investment fund. Its investment objective is to seek total return, resulting from a high level of current income, with an emphasis on providing tax-advantaged dividend income.
About DCTH Delcath Systems Inc.
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.